- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06183229
Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza
February 2, 2024 updated by: POLYSAN Scientific & Technological Pharmaceutical Company
Double-blind Placebo-controlled Randomized Trial of Efficacy and Safety of Cycloferon, Enteric-coated Tablets, 150 mg, for Post-exposure Prophylaxis of Acute Respiratory Viral Infection and Influenza
Influenza and other acute respiratory viral infections remain practically uncontrollable diseases due to the high variability of the antigenic structure of influenza viruses and the heterogeneity of pathogens of acute respiratory infections.
Therefore, for the prevention and treatment of influenza, acute respiratory viral infections and herpes infections, it is relevant to develop drugs - immunomodulators that mobilize the reserves of nonspecific and specific immune systems and enhance the effects of these systems against the pathogens.
The drug CYCLOFERON, 150 mg, enteric-coated tablets, contains the active substance meglumine acridone acetate, which is an interferon inducer.
Interferons are the most important system of innate immunity, which has antiviral and immunomodulatory effects, and can protect the body from infection with a virus, and in case of infection, fight the causative agent of the disease.
The planned clinical trial of the efficacy and safety of the drug CYCLOFERON in the dosage form of a tablet will study its ability to prevent influenza and other respiratory viral infections in adults who have already had close contact with patients with manifest disease.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
578
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Aleksey L Kovalenko, Doc Biol Sci
- Phone Number: +7 (812) 448-22-22
- Email: science@polysan.ru
Study Locations
-
-
-
Saint Petersburg, Russian Federation, 196143
- Recruiting
- Research Center for Eco-safety, Ltd.
-
Contact:
- Vasily B Vasilyuk, MD, PhD
- Phone Number: +79013044248
- Email: vasilyuk_vb@ecosafety.ru
-
Saint-Petersburg, Russian Federation
- Recruiting
- City Outpatient Clinic #117
-
Contact:
- Diana N Alpenidze
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male and female subjects aged 18 to 65 years inclusive.
- Written informed consent.
- Co-living with persons who has developed influenza or other acute respiratory viral infection, diagnosed no more than 3 days ago.
- No signs of acute respiratory viral infection, influenza or COVID-19 at the time of inclusion in the study.
- For women with preserved reproductive potential - a negative pregnancy test and consent to use approved methods of contraception during the entire period of participation in the study; for men - consent to use approved methods of contraception during the entire period of participation in the study and for 3 weeks after the end of the study.
Exclusion Criteria:
- Known or suspected hypersensitivity to meglumine acridone acetate and/or any other component of the drug/placebo.
- Lactose intolerance
- Diseases of the digestive system in the acute stage (erosions, gastric and/or duodenal ulcers, gastritis and duodenitis).
- History of allergic reactions.
- Decompensated liver cirrhosis.
- Diseases of the thyroid gland.
- Congenital or acquired immunodeficiency.
- Signs of acute respiratory viral infection, influenza or COVID-19 at the time of inclusion.
- Positive result of a rapid test for the presence of SARS-CoV-2 at the time of screening.
- Vaccination to prevent COVID-19 and/or influenza within 6 months before screening, planned vaccination during a clinical trial.
- History of positive test result for HIV types 1 or 2.
- Pregnancy or breastfeeding period (for women).
- Alcoholism, drug addiction, substance and/or drug abuse in history and/or at the time of screening.
- Participation in another clinical trial within 3 months before inclusion.
- Subject is already receiving cycloferon.
- Subject is receiving prohibited therapy or was receiving it within 30 days prior to screening.
- Failure to observe the subject during the study period.
- Other reasons that, in the opinion of the researcher, prevent the subject from participating in the study or create an unreasonable risk (for example, a history of autoimmune diseases, etc.).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cycloferon
Intake of Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.
|
Cycloferon, enteric-coated tablets, 150 mg, 4 tablets (600 mg) per day on days 1, 2, 4, 6 and 8.
Other Names:
|
Placebo Comparator: Placebo
Intake of Placebo, 4 tablets per day, on days 1, 2, 4, 6 and 8.
|
Placebo tablets, 4 tablets per day on days 1, 2, 4, 6 and 8
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of influenza/other acute respiratory viral infection in the study groups
Time Frame: 14 days
|
the proportion of subjects with clinically manifest and laboratory confirmed influenza or other acute respiratory viral infection, developed within days 1-14 of the study.
|
14 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Tatiana V Kharitonova, MD PhD, STPF POLYSAN
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 15, 2023
Primary Completion (Estimated)
September 15, 2025
Study Completion (Estimated)
October 1, 2025
Study Registration Dates
First Submitted
December 13, 2023
First Submitted That Met QC Criteria
December 13, 2023
First Posted (Actual)
December 27, 2023
Study Record Updates
Last Update Posted (Estimated)
February 5, 2024
Last Update Submitted That Met QC Criteria
February 2, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Respiratory Tract Diseases
- Disease Attributes
- Orthomyxoviridae Infections
- Infections
- Communicable Diseases
- Virus Diseases
- Influenza, Human
- Respiratory Tract Infections
- Physiological Effects of Drugs
- Immunologic Factors
- Interferon Inducers
- 10-carboxymethyl-9-acridanone
Other Study ID Numbers
- CCF-III-TAB-2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Avian Influenza | H1N1 InfluenzaUnited States